| Literature DB >> 25332472 |
Sonia Hernández-Cordero1, Simón Barquera2, Sonia Rodríguez-Ramírez2, María Angeles Villanueva-Borbolla2, Teresa González de Cossio2, Juan Rivera Dommarco2, Barry Popkin3.
Abstract
BACKGROUND: Mexico's sugar-sweetened beverage (SSB) intake is among the highest globally. Although evidence shows that increases in SSB intake are linked with increased energy intake, weight gain, and cardiometabolic risks, few randomized clinical trials have been conducted in adults.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25332472 PMCID: PMC6457091 DOI: 10.3945/jn.114.193490
Source DB: PubMed Journal: J Nutr ISSN: 0022-3166 Impact factor: 4.798
FIGURE 1Flow of participants through the trial. 1Phone screening criteria: age and reported BMI (confirmed at study site visit). 2Based on attendance at last appointment. EP, education provision; WEP, water and education provision.
Body composition, dietary intake, and physical activity by intervention group
| Study time point |
| ||||||
|---|---|---|---|---|---|---|---|
| Baseline | 3 mo | 6 mo | 9 mo | Treatment | Time | Treatment × time | |
| Weight, | 0.50 | 0.04 | 0.4 | ||||
| WEP | 76.9 ± 0.3 | 76.4 ± 0.3 | 75.6 ± 0.3 | 75.7 ± 0.3 | |||
| EP | 76.0 ± 0.3 | 75.6 ± 0.3 | 75.3 ± 0.3 | 75.3 ± 0.3 | |||
| BMI, | 0.90 | 0.04 | 0.40 | ||||
| WEP | 31.0 ± 0.1 | 30.6 ± 0.1 | 30.5 ± 0.1 | 30.5 ± 0.1 | |||
| EP | 31.0 ± 0.1 | 30.8 ± 0.1 | 30.7 ± 0.1 | 30.7 ± 0.1 | |||
| Body fat, | 0.70 | 0.40 | 0.90 | ||||
| WEP | 42.5 ± 0.1 | — | — | 41.6 ± 0.1 | |||
| EP | 42.2 ± 0.1 | — | — | 41.5 ± 0.2 | |||
| Waist circumference, | 0.70 | 0.40 | 0.80 | ||||
| WEP | 98.3 ± 0.3 | 97.8 ± 0.3 | 96.9 ± 0.2 | 97.3 ± 0.3 | |||
| EP | 98.5 ± 0.3 | 97.9 ± 0.3 | 97.9 ± 0.3 | 97.3 ± 0.3 | |||
| Total energy intake, | 0.30 | <0.001 | 0.90 | ||||
| WEP | 2015 ± 14 | 1461 ± 14 | 1440 ± 13 | 1430 ± 11 | |||
| EP | 2054 ± 15 | 1608 ± 13 | 1577 ± 12 | 1485 ± 11 | |||
| Energy intake from solid foods, | 0.09 | 0.10 | 0.07 | ||||
| WEP | 1497 ± 13 | 1212 ± 11 | 1211 ± 11 | 1181 ± 10 | |||
| EP | 1549 ± 13 | 1247 ± 10 | 1203 ± 10 | 1109 ± 8 | |||
| Beverages with sugar | |||||||
|
| 0.40 | <0.001 | <0.001 | ||||
| WEP | 1127 ± 11 | 500.0 ± 11 | 45 ± 12 | 418 ± 11 | |||
| EP | 1094 ± 11 | 807.0 ± 14 | 890 ± 17 | 796 ± 13 | |||
|
| 0.80 | <0.001 | <0.001 | ||||
| WEP | 407 ± 4 | 164.0 ± 4 | 155.0 ± 4 | 155 ± 4 | |||
| EP | 409 ± 4 | 283.0 ± 6 | 310.0 ± 6 | 292 ± 6 | |||
|
| 0.30 | <0.001 | <0.001 | ||||
| WEP | 21.0 ± 0.2 | 10.6 ± 0.2 | 10.1 ± 0.3 | 10.7 ± 0.3 | |||
| EP | 20.0 ± 0.2 | 16.9 ± 0.3 | 19.9 ± 0.4 | 19.3 ± 0.4 | |||
| Water consumption, | 0.20 | <0.001 | <0.001 | ||||
| WEP | 737 ± 15 | 1713.0 ± 18 | 1842 ± 20 | 1942 ± 22 | |||
| EP | 824 ± 18 | 967.0 ± 18 | 1015 ± 22 | 1065 ± 22 | |||
| Physical activity, | 0.99 | 0.91 | 0.79 | ||||
| WEP | 1.455 ± 0.004 | 1.445 ± 0.004 | 1.454 ± 0.005 | 1.477 ± 0.011 | |||
| EP | 1.455 ± 0.004 | 1.452 ± 0.004 | 1.489 ± 0.005 | 1.485 ± 0.007 | |||
Values are means ± SEs. EP, education provision; MET, metabolic equivalent; WEP, water and education provision.
Data were analyzed by using intent-to-treat analysis, 10 imputations (n = 240). Repeated-measures mixed-effects model analysis was used to test the mean through time.
There was no difference between groups at baseline in dietary intake or physical activity (all P ≥ 0.1).
Measured at baseline and 9 mo only.
Change in metabolic syndrome indicators, hydration status, and dietary intake by intervention group
| Change from baseline |
| |||||
|---|---|---|---|---|---|---|
| 3 mo | 6 mo | 9 mo | 3 mo | 6 mo | 9 mo | |
| Plasma TGs, | 0.70 | 0.30 | 0.30 | |||
| WEP | 5.60 ± 8.00 | −2.40 ± 9.10 | −5.70 ± 10.0 | |||
| EP | 1.80 ± 6.60 | 13.6 ± 11.3 | 10.7 ± 9.90 | |||
| Total cholesterol, | 0.60 | 0.60 | 0.70 | |||
| WEP | 1.50 ± 4.70 | 5.80 ± 5.60 | 1.90 ± 8.70 | |||
| EP | 5.70 ± 5.20 | 1.20 ± 7.60 | −3.00 ± 8.90 | |||
| LDL cholesterol, | 0.50 | 0.30 | 0.40 | |||
| WEP | 1.10 ± 3.50 | 4.90 ± 4.00 | 0.200 ± 4.00 | |||
| EP | 4.60 ± 3.70 | −1.60 ± 4.60 | −5.00 ± 4.70 | |||
| HDL cholesterol, | 0.40 | 0.90 | 0.60 | |||
| WEP | −0.300 ± 1.30 | 1.90 ± 8.50 | 0.300 ± 1.40 | |||
| EP | 1.20 ± 1.40 | 1.10 ± 4.60 | −1.70 ± 1.80 | |||
| Fasting plasma glucose, | 0.90 | 0.90 | 0.90 | |||
| WEP | 0.0400 ± 1.50 | 0.60 ± 1.90 | 1.20 ± 1.70 | |||
| EP | 0.200 ± 1.40 | 0.90 ± 2.20 | 1.70 ± 2.80 | |||
| HbA1c, | — | — | 0.30 | |||
| WEP | — | — | −0.0300 ± 0.0300 | |||
| EP | — | — | 0.0200 ± 0.0300 | |||
| Systolic blood pressure, | 0.30 | 0.50 | 0.60 | |||
| WEP | 0.0500 ± 0.900 | −2.40 ± 1.00 | −0.90 ± 1.20 | |||
| EP | −1.30 ± 1.00 | −3.80 ± 1.40 | −2.80 ± 1.70 | |||
| Diastolic blood pressure, | 0.50 | 0.50 | 0.80 | |||
| WEP | −1.00 ± 0.900 | −3.70 ± 1.00 | −3.40 ± 1.10 | |||
| EP | −1.90 ± 0.800 | −4.70 ± 1.10 | −3.90 ± 1.50 | |||
| Serum osmolality, | — | — | 0.80 | |||
| WEP | — | — | −2.60 ± 3.30 | |||
| EP | — | — | −1.30 ± 3.00 | |||
| Urine osmolality, | — | — | 0.008 | |||
| WEP | — | — | −131 ± 38.0 | |||
| EP | — | — | 3.10 ± 42.5 | |||
| Weight, | 0.06 | 0.10 | 0.40 | |||
| WEP | −1.0 ± 0.2 | −1.4 ± 0.3 | −1.2 ± 0.4 | |||
| EP | −0.5 ± 0.2 | −0.7 ± 0.3 | −0.8 ± 0.4 | |||
| BMI, | 0.07 | 0.10 | 0.40 | |||
| WEP | −0.40 ± 0.08 | −0.54 ± 0.11 | −0.50 ± 0.14 | |||
| EP | −0.20 ± 0.08 | −0.30 ± 0.14 | −0.33 ± 0.15 | |||
| Body fat, | — | — | 0.90 | |||
| WEP | — | — | −0.8 ± 0.4 | |||
| EP | — | — | −0.8 ± 0.6 | |||
| Waist circumference, | 0.10 | 0.20 | 0.70 | |||
| WEP | −1.0 ± 0.3 | −1.4 ± 0.3 | −1.0 ± 0.4 | |||
| EP | −0.5 ± 0.3 | −0.6 ± 0.5 | −1.3 ± 0.7 | |||
| Total energy intake, | 0.20 | 0.30 | 0.80 | |||
| WEP | −553 ± 56 | −575 ± 54 | −585 ± 55 | |||
| EP | −447 ± 52 | −478 ± 60 | −567 ± 66 | |||
| Energy intake from solid foods, | 0.80 | 0.40 | 0.10 | |||
| WEP | −285 ± 46 | −285 ± 46 | −315 ± 47 | |||
| EP | −302 ± 44 | −347 ± 53 | −440 ± 58 | |||
| Beverages with sugar | ||||||
|
| <0.001 | <0.001 | <0.001 | |||
| WEP | −628 ± 50 | −675 ± 50 | −709 ± 59 | |||
| EP | −286 ± 53 | −198 ± 71 | −297 ± 59 | |||
|
| <0.001 | <0.001 | 0.001 | |||
| WEP | −243 ± 17 | −252 ± 16 | −252 ± 19 | |||
| EP | −125 ± 20 | −96 ± 24 | −115 ± 27 | |||
|
| <0.001 | <0.001 | <0.001 | |||
| WEP | −10.5 ± 0.9 | −11.0 ± 1.2 | −10.4 ± 1.3 | |||
| EP | −3.5 ± 1.0 | −0.4 ± 1.6 | −1.0 ± 1.5 | |||
| Water consumption, | <0.001 | <0.001 | <0.001 | |||
| WEP | 976 ± 67 | 1,109 ± 88 | 1,210 ± 102 | |||
| EP | 142 ± 67 | 190 ± 92 | 239 ± 91 | |||
Values are means ± SEs. Data were analyzed by using intent-to-treat analysis, 10 imputations. Changes were calculated from baseline to 3, 6, and 9 mo without adjustments for covariates; n = 120 for WEP and n = 120 for EP. A repeated-measures mixed-effects model analysis was used to test the mean through time, all P > 0.05 (data not shown). EP, education provision; HbA1c, glycosylated hemoglobin; mOsm, milliosmole; WEP, water and education provision.
Measured at baseline and 9 mo only.
Metabolic syndrome risk indicators and hydration status by intervention group
| Study time point |
| ||||||
|---|---|---|---|---|---|---|---|
| Baseline | 3 mo | 6 mo | 9 mo | Treatment | Time | Treatment × time | |
| Plasma TGs, | 0.20 | 0.20 | 0.10 | ||||
| WEP | 155 ± 2.10 | 161 ± 2.60 | 157 ± 2.30 | 149 ± 2.80 | |||
| EP | 150 ± 1.90 | 152 ± 1.70 | 164 ± 2.60 | 161 ± 2.70 | |||
| Plasma total cholesterol, | 0.30 | 0.50 | 0.30 | ||||
| WEP | 188 ± 1.30 | 190 ± 1.20 | 191 ± 1.30 | 187 ± 1.20 | |||
| EP | 188 ± 1.30 | 195 ± 1.40 | 192 ± 1.40 | 186 ± 1.20 | |||
| Plasma LDL cholesterol, | 0.10 | 0.20 | 0.09 | ||||
| WEP | 103 ± 0.900 | 105 ± 0.900 | 106 ± 0.900 | 105 ± 0.900 | |||
| EP | 106 ± 0.800 | 111 ± 1.00 | 106 ± 1.10 | 102 ± 0.900 | |||
| Plasma HDL cholesterol, | 0.30 | 0.10 | 0.10 | ||||
| WEP | 52.5 ± 0.400 | 52.6 ± 0.400 | 55.0 ± 0.400 | 52.7 ± 0.400 | |||
| EP | 53.2 ± 0.300 | 53.5 ± 0.400 | 52.7 ± 0.400 | 51.5 ± 0.300 | |||
| Fasting plasma glucose, | 0.90 | 0.80 | 0.90 | ||||
| WEP | 90.2 ± 0.400 | 90.0 ± 0.300 | 90.5 ± 0.300 | 90.7 ± 0.400 | |||
| EP | 90.2 ± 0.300 | 90.3 ± 0.300 | 90.5 ± 0.400 | 91.1 ± 0.300 | |||
| HbA1c, | 0.30 | 0.20 | 0.30 | ||||
| WEP | 5.80 ± 0.0100 | — | — | 5.82 ± 0.0100 | |||
| EP | 5.80 ± 0.0100 | — | — | 5.80 ± 0.0100 | |||
| Systolic blood pressure, | 0.10 | 0.80 | 0.30 | ||||
| WEP | 100 ± 0.300 | 100 ± 0.300 | 97.6 ± 0.300 | 98.0 ± 0.300 | |||
| EP | 102 ± 0.300 | 100 ± 0.300 | 98.3 ± 0.300 | 98.6 ± 0.400 | |||
| Diastolic blood pressure, | 0.20 | 0.10 | 0.40 | ||||
| WEP | 68.3 ± 0.800 | 67.3 ± 0.200 | 64.6 ± 0.200 | 63.9 ± 0.200 | |||
| EP | 70.0 ± 0.700 | 68.1 ± 0.200 | 65.3 ± 0.300 | 65.5 ± 0.300 | |||
| Serum osmolality, | 0.40 | 0.60 | 0.90 | ||||
| WEP | 296 ± 0.800 | — | — | 293 ± 0.500 | |||
| EP | 293 ± 0.600 | 291 ± 0.400 | |||||
| Urine osmolality, | 0.30 | 0.01 | 0.05 | ||||
| WEP | 707 ± 7.70 | — | — | 581 ± 7.70 | |||
| EP | 701 ± 6.60 | — | — | 701 ± 9.20 | |||
Values are means ± SEs. EP, education provision; HbA1c, glycosylated hemoglobin; mOsm, milliosmole; WEP, water and education provision.
Data were analyzed by using intent-to-treat analysis, 10 imputations (n = 240). Repeated-measures mixed-effects model analysis was used to test the mean through time.
There was no difference between groups at baseline in any of the outcomes or indicators of hydration status (all P ≥ 0.1).
Measured at baseline and at 9 mo only.
FIGURE 2Effects of the intervention at 9 mo on the basis of baseline weight status on plasma TG changes from baseline to 9 mo (A) and prevalence of metabolic syndrome at 9 mo (B). Values are means ± SEs (A) and percentages (95% CIs) (B). The model for panel A is a simple linear regression model including as an outcome variable the change in plasma TGs from baseline to 9 mo and as predictor variables the treatment group (WEP = 1, EP = 0) and BMI at baseline (obese = 1, overweight = 0). Interaction term: treatment × BMI at baseline; n = 184. The model for panel B is a logistic regression model, adjusted by prevalence of metabolic syndrome at baseline, treatment (WEP = 1, EP = 0), BMI at baseline (obese = 1, overweight = 0), change in physical activity from baseline to 9 mo, age at baseline, and interaction of treatment × BMI at baseline; n = 179. *Different from EP, P < 0.05. EP, education provision; WEP, water and education provision.
Baseline characteristics of study participants
| ITT ( | ||
|---|---|---|
| WEP ( | EP ( | |
| Age, | 33.5 ± 6.7 | 33.3 ± 6.7 |
| Parity, | ||
| Nulliparous | 34 (28.3) | 27 (22.5) |
| Multiparous | 86 (71.7) | 93 (77.5) |
| Marital status, | ||
| Married/living with someone | 69 (57.5) | 78 (65.0) |
| Not married/living with someone | 51 (42.5) | 42 (35.0) |
| Education, | ||
| Incomplete: middle school or less | 4 (3.3) | 6 (5.0) |
| Complete: middle school and high school | 47 (39.1) | 61 (50.8) |
| Technical school | 19 (15.8) | 16 (13.3) |
| Professional or higher | 50 (41.6) | 37 (30.8) |
| BMI classification, | ||
| Overweight | 56 (46.6) | 54 (45.0) |
| Obese | 64 (53.3) | 66 (55.0) |
| Smoking status, | ||
| Yes | 39 (32.5) | 36 (30.0) |
| No | 81 (67.5) | 84 (70.0) |
| Socioeconomic level index | 0.11 ± 1.34 | −0.14 ± 1.33 |
Values are means ± SDs unless otherwise indicated. Data were analyzed by using ITT analysis with 10 imputations (n = 240). EP, education provision; ITT, intent-to-treat; WEP, water and education provision.